Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients: A Randomized Clinical Trial Study.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of lupus (sle) in this randomized controlled trial publication.

Who Took Part

PubMed tags the participants as women only.

A double blind, randomized, controlled trial was conducted on female outpatients aged 18-60 years with SLE, consecutively recruited from September to December 2021 at Cipto Mangunkusumo Hospital.

Sixty subjects who met the research criteria were randomized and equally assigned into the cholecalciferol and placebo groups.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

PubMed files the paper under topics including Cholecalciferol, Dietary Supplements, Lupus Erythematosus, Systemic, Quality of Life, Vitamin D, Vitamin D Deficiency and Vitamins.

The authors tagged it with the keywords disease activity and systemic lupus erythematosus.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with lupus (sle).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Acta medica Indonesiana), a journal based in Indonesia.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Lupus (SLE) research.